Merck admits Keytruda data misleading
In December 2015, Merck Sharp and Dohme (MSD) issued a “Dear Doctor” letter in which they corrected the trial data given to doctors, overstating the benefits of the pembrolizumab (trade name Keytruda), the melanoma drug at the centre of MSD’s campaign to gain public funding for the drug.
According to an article by Stacey Kirk that was posted on the Stuff website on 16 December 2015, MSD was “forced to amend trial data” presented at the December conference of the New Zealand Society of Oncologists (NZSO). (1)
In the letter, MSD explained that the materials produced for NZSO in November were derived from a slide previously presented at the American Society of Clinical Oncology (ASCO).
“Despite our best intent, having reviewed this and in the absence of published updated duration date for this patient cohort; the information on this slide does not support the 30 months claim” – the claim being that most patients that responded to first-line treatment were still responding at 30 months. Pembrolizumab is so new that long-term survival data does not yet exist.
This uncertainty about its long-term benefits, as well as the percentage of cancer patients who will benefit , and its high cost are why PHARMAC’s experts committee gave it a low-priority status.
As an article in the December issue of the AWHC newsletter pointed out the campaign to get the government to take funding for pembrolizumab out of PHARMAC’s hands quickly became a political issue. In December 2015 Andrew Little sent out a petition urging New Zealanders to ask John Key to fund the drug, and “make sure John Key stands up to people like Jonathon Coleman and makes the right decision."
The current government’s election bribe in 2008 to overrule PHARMAC’s decision to decline funding for 52 weeks of Herceptin was a very costly mistake in that it completely destroyed PHARMAC’s ability to negotiate with Roche, the drug’s manufacturer, on all its products, not just Herceptin.
Having lost its bargaining power once and paid a huge price for it, John Key and Jonathon Coleman are understandably not keen to repeat the same mistake with MSD over pembrolizumab, especially when the drug company has already had to admit to overstating the benefits of its latest overpriced drug.
It is therefore extremely disappointing that in an effort to win votes in next year’s election, the Labour Party would ignore the lessons that have been learned, and interfere with the integrity of the public health system.
Keytruda, Herceptin and PHARMAC
There have been numerous stories in the media recently about how those with invasive cancers – melanoma and lung cancer in particular – would be saved if only PHARMAC would fund their treatment with the latest potentially-life saving drug known as pembrolizumab, sold under the trade name Keytruda.
Pembrolizumab is the first of a new class of immunotherapy drugs, called anti PD-1 inhibitors, which work by activating the body’s own immune system to attack the cancer cells.
In trials pembrolizumab was shown to be twice as effective as chemo-therapy, halting and even shrinking tumour growth for 34% of patients with advanced malignant melanomas. The latest clinical trial results presented at ASCO 2015, showed 80% of advanced melanoma patients who had received no prior treatment, experienced tumour shrinkage and 14 percent had no detectable cancer, at a median follow up of 15 months.
The drug is so new that long-term survival data does not yet exist, but oncologists are reporting that around 30% of the patients who respond to the new drug can expect to see their lives significantly extended.
While the drug has been approved for use in New Zealand, it is not yet funded by Pharmac. Patients need a new cycle of treatment every three weeks and, at a cost of around $10,000 per patient, per cycle, depending on weight, the treatment remains out of reach for the vast majority of patients. As PHARMAC’s experts committee have given it a low-priority status because of the uncertainty about its benefits and its high cost – about $300,000 a patient for two years’ treatment – the drug is likely to remain out of reach for most patients for some time.
Some media commentators have compared the campaign for the government to fund Keytruda with the campaign that resulted in the current government, as part of an election bribe, agreeing to fund 52 weeks of Herceptin as opposed to the nine weeks that PHARMAC had agreed to fund. (1)
While the former Health Minister Tony Ryall claimed that providing funding for 12 months of Herceptin was one of the highlights of his time as Minister of Health, there is now sufficient research evidence that overall the nine-week treatment regime is as good as 52 weeks, and the government was misguided in overruling PHARMAC’s decision to refuse to fund the 52-week treatment option.
When the current Minister of Health, Jonathon Coleman was recently asked by TV3’s Paul Henry whether overriding PHARMAC on Herceptin was “the right thing to do,” Coleman said “I don’t think it was actually, and I think history has shown that. The research shows that nine weeks which were funded previously was just as good as 52 weeks, but I think lessons have been learned.” (2)
It also worth noting that many women, when faced with all that the 52-week chemotherapy regime involves have chosen the nine weeks, partly because of the serious side effects of Herceptin and also because of the huge demands on their time and energy that 52 weeks of chemotherapy entails.
With the National government having admitted it made a mistake overruling PHARMAC’s decision on Herceptin, it is extremely disappointing to see Labour’s Andrew Little and Annette King promising to take the decision on Keytruda out of PHARMAC’s hands. As a recent editorial in the NZ Herald under the heading “We must put our trust in Pharmac” stated:
“If a Government provides additional funds to cover the costs of a particular drug, it does not upset the careful decisions that PHARMAC has to make about the best use of its budget. But each time a Government does so, it reduces the integrity and fairness of the public health system. It is easy to make emotional decisions, especially where cancer is concerned.” (3)
It is also disappointing that the media is so reluctant to challenge the pharmaceutical industry’s figures about the cost of getting a new drug to market. Claims that it can cost between $1 billion to $3 billion are hugely inflated. It has been common knowledge for over a decade that the drug industry’s claims about their research and development costs are lies because of what they include in their expenditure columns. (4) (5)
Merck, Sharpe and Dohme, the manufacturer of pembrolizumab, is just one of the drug companies that is currently holding cancer sufferers to ransom. Their research, drug development and marketing practices have resulted in some eye-watering fines, including a $322 million fine for an illegal marketing campaign involving Vioxx, its blockbuster arthritis drug. And the costs of the drug company’s marketing campaigns – legal and illegal – are included in the costs they quote.
As the author of a recent letter to the editor in the NZ Herald stated, “some of the nation’s worst drug dealers aren’t peddling on street corners, they’re occupying corporate suites.” In Merck, Sharpe and Dohme’s case they occupy a pretty impressive building at 109 Carlton Gore Road in Newmarket, Auckland.
It is long past time for health consumer groups, patients, and cancer sufferers in particular, to take a stand. Instead of lobbying our governments we need to start campaigning against the deceipt and lies of the pharmaceutical industry which is currently holding the world to ransom with its overpriced drugs.
See also -
A NEW PILL AVAILABLE FOR FEMALE SEXUAL DYSFUNCTION
First the pharmaceutical industry invented the diagnosis – hypoactive sexual desire disorder (HSDD) – and then they set about trying to find a drug for this “unmet medical need” in women. The “new” drug, flibanserin, is being hailed as the new Viagra for women, but it isn’t. It is actually a drug which the FDA decided in 2010 wasn’t sufficiently effective – not much better than a placebo – and the side effects far outweighed the very doubtful benefits.
Flibanserin was originally owned by Boehringer Ingelheim and had been investigated as an antidepressant. It changes brain chemistry, not blood flow, as Viagra does. The drug company tried again in 2013 and then managed to offload the lemon on to Sprout Pharmaceuticals who mounted a campaign to pressure the FDA to approve more drugs to treat female sexual dysfunction, especially this one, accusing it of having a gender bias. The FDA convened an advisory panel which has recently urged the FDA to approve the drug.
Among other things the drug has the potential for the use of hormonal contraceptives and alcohol to make its side effects – nausea, sleepiness, dizziness, fainting, and low blood pressure – worse. It is aimed at menopausal women, and would have to be taken daily on a long-term basis.
Flibanserin, the failed antidepressant, may not have measured up in the past, but buckets of money and a public relations campaign to rebrand it as libido-in-a-pill has ensured it is coming to a pharmacy near you.
PHARMAC CONSULTS ON ITS DECISION NOT TO FUND SOLIRIS
PHARMAC is seeking feedback on its proposal to decline a funding application for eculizumab, also known as Soliris. (1) As noted in the February issue of the AWHC newsletter, Soliris which is manufactured by Alexion Pharmaceuticals, is the world’s most expensive drug – the cost of treating one PNH patient for a year is over $600,000.
PNH (paroxysmal nocturnal haemo-globinuria) is an extremely rare blood and immune system disorder. It is an acquired disease characterised by the destruction of red blood cells, blood clots, impaired bone marrow function and a risk of developing leukaemia. The median survival after diagnosis is 10 years; however some patients can survive for decades with only minor symptoms. There is currently no known cure for PNH.
Current treatment in New Zealand for PNH aims to relieve symptoms rather than cure the condition, and includes blood transfusion to treat anaemia, immune suppression with steroids to suppress ongoing red blood cell destruction and anticoalgulation with warfarin to prevent or treat blood clots. (1)
Soliris/eculizumab is given via an intravenous infusion administered to patients fortnightly in a hospital setting. It is not a cure but it relieves the symptoms associated with PNH and it needs to be used for the rest of the patient’s life.
PHARMAC received an application from Alexion Pharmaceuticals to fund Soliris in November 2011. Clinical advisors considered the application at the Pharmacology and Therapeutics Advisory Committee (PTAC) in February 2012, at the Haemotolgy Subcommittee in August 2012, and at February and March 2013 PTAC meetings. The minutes of these meetings are available on PHARMAC’s website.
PHARMAC’s consultation document explains that the reason it is proposing to decline funding is because the price requested by the drug company is extreme.
The New Zealand patient group that was established a year ago, and Dr Humphrey Pullon, a consultant haematologist in Hamilton, appeared on Morning Report on 22 May arguing that PHARMAC had overestimated the numbers of patients (12–20 patients instead of 8–10 patients) who would be considered for treatment with this drug and that the price that Alexion Pharmaceuticals had offered the drug to PHARMAC was the lowest in the world. (2)
Alexion Pharmaceuticals has funded both the Australian and New Zealand campaigns for drug. An email sent to Dr Humphrey Pullon several months ago asking about his ties to the drug company has not been replied to.
“GIVE US THE $600,000 MIRACLE DRUG”
At the end of January 2013 the front page of the NZ Herald featured a by now familiar story of a small group of patients that were desperately lobbying for a very expensive drug. (1) In this case it was the world’s most expensive drug – costing $500,000 a year per patient. (2)
The drug in this story is eculizumab, otherwise known as Soliris, and it is used to treat patients with PNH (paroxysmal nocturnal haemoglobinuria) which is an extremely rare blood and immune system disorder. The Herald article stated that in New Zealand “up to 20 people are thought to have PNH” with eight of them considered candidates for Soliris.
PNH is an acquired rather than genetic disease characterised by the destruction of red blood cells, blood clots, impaired bone marrow function, and a 3-5% risk of developing leukaemia. The red blood cells become prone to destruction by parts of the person’s own immune system due to the lack of a special protein which normally protects the red blood cells from being destroyed by the immune system. It is closely related to aplastic anaemia, and up to 30% of newly diagnosed cases of PNH evolve from aplastic anaemia. The median survival after diagnosis is 10 years; however some patients can survive for decades with only minor symptoms. (3)
The drug company
Soliris is manufactured by Alexion Pharmaceuticals which has given its new drug to three of the eight New Zealand patients with PNH under a compassionate access scheme. It is not clear why the drug company has chosen to fund only three of the eight.
Towards the end of the NZ Herald article it was revealed that there was a New Zealand support group for patients with PNH and they had begun this lobbying campaign which was being funded by Alexion. A follow-up editorial in the Herald on Sunday reported that the support group had been given an “unrestricted educational grant” from Alexion and the campaign was being orchestrated by Viva, a Sydney PR firm that represents Alexion Pharmaceuticals. (4)
The editorial referred to the fact that “Alexion is a NASDAQ-listed firm that last year projected a net revenue of $1.35 billion from sales of Soliris around the world.” (4) $1.35 billion from just one drug! It’s enough to make the Ministry of Health’s eyes water. Alexion Pharmaceuticals' website states that "the Company is also developing a portfolio of four innovative drug candidates beyond eculizumab for the treatment of additional severe and ultra-rare disorders."
The editorial continued: Alexion is “not just a world leader in the medical laboratory; it’s a world leader in arm-twisting governments to fund its extortionately-priced drug.” The pressure is being applied by slick campaigns that appear to be run by patient groups, but are in fact being run by Alexion’s PR firms in Australia and Canada.
The New Zealand patient group which was established less than a year ago has a very professional website that features a video of Dr Humphrey Pullon, a consultant haematologist in Hamilton, alerting us to “the developing public scandal that is seriously ill PNH patients being denied access to a life-saving treatment.” (5) His promotion of Soliris is even accompanied by a soundtrack. There is also an online “PNH petition for life” for us all to sign or download.
According to the Herald on Sunday, “these campaigns are effective: 24,000 Australians signed a petition supporting the nation’s 70 PNH sufferers, forcing the federal government to begin funding the drug in 2011. The Canadian government also capitulated – though that nation’s provinces banded together to knock down Alexion’s prices. They were aided in their hardball negotiations by the discovery that Alexion was supplying Soliris to the US at half the price it was quoting to the rest of the world.” (4)
A visit to the Wikipedia website on Soliris in the course of researching this article revealed that the site had recently been updated to include the fact that New Zealand is the only country in the OECD that does not fund Soliris. Its reference is the TV3 news item on 24 January that repeated what was in the NZ Herald article that morning. This “important” fact also features on the NZ PNH support group’s website.
A link on another PNH support group’s website to an article on long-term treatment with Soliris published in 2011 in Blood, the weekly publication of the American Society of Hematology, showed that all the researchers had financial ties to Alexion Pharmaceuticals. (6)
Another dangerous drug
The drug.com website states that “Soliris affects your immune system, and using this medication may increase your risk of serious infection such as meningitis. You must be vaccinated against meningococcal infection at least 2 weeks before you start treatment with Soliris. If you have been vaccinated in the past, you may need a booster dose.” (7)
Alexion Pharmaceuticals’ own website states that the US product label for Soliris includes a boxed warning advising that “life-threatening and fatal meningococcal infections have occured in patients treated with Soliris. Meningococcal infection may become rapidly life-threatening or fatal if not recognised and treated early.” (8)
Of course this fact isn’t included on the New Zealand patient group website. Nor is the fact that there are no vaccines for some strains of meningococcal infections, and that some like the MeNZB vaccine only last for a couple of years, if that. What is on the website is the claim that “Our only hope for survival rests in the hands of PHARMAC.”
Actually, it doesn’t. It rests in the hands of Alexion Pharmaceuticals which can certainly afford to lower the price of its obscenely over-priced drug. The PNH Support Association of NZ should be lobbying Alexion Pharmaceuticals, not NZ taxpayers.
6. Richard Kelly et al. “Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.” Blood. 23 June 2011 Volume 117, Number 25.
For the latest on the battle for the truth about Tamiflu go to -
THE BATTLE FOR THE TRUTH ABOUT TAMIFLU
In an unprecedented move the British Medical Journal (BMJ) has begun an online open data campaign in an effort to achieve independent scrutiny of data from clinical trials. The major target of its first initiative is Roche, the pharmaceutical company that manufactures the antiviral drug oseltamivir, more commonly known as Tamiflu. On its website the BMJ states that “working with others, we seek to highlight problems caused by lack of access to data, and we welcome any suggestions on how to take things further.” (1)
Around 2008/2009 New Zealand was one of many countries around the world that began spending millions of dollars on stockpiling Tamiflu which Roche claimed was the drug of choice for the treatment and prevention of influenza A and B viruses. When the H1N1 (swine flu) pandemic began in mid 2009, demand for Tamiflu skyrocketed.
How effective is Tamiflu?
The US Department of Health and Human Services said it would save lives and reduce hospital admissions. The European Medicines Agency said it would reduce complications. The Australian and New Zealand health agencies agreed. (2) But where is the evidence to support these claims?
This is where the Cochrane Collaboration comes into the picture. The Cochrane Collaboration is a vast independent non-profit international collaboration of academics that produces hundreds of systematic reviews on medicines every year. Given the enormous sums of money that were now being spent on Tamiflu, the UK and Australian governments asked the Cochrane Respiratory Diseases Group to update its earlier reviews on Tamiflu.
The previous review published in 2008 had found some evidence that Tamiflu did indeed reduce the rate of complications associated with the flu virus. However, an online comment posted by a Japanese paediatrician called Keiji Hayashi alerted Tom Jefferson, the head of the Cochrane Respiratory Group that he had made a mistake. According to Ben Goldacre, the author of “Bad Pharma,” this comment triggered “a revolution in our understanding of how evidence-based medicine should work.” (2)
Basically what Keiji Hayashi pointed out was that Tom Jefferson’s positive findings were based on data from one paper, an industry-funded meta-analysis which summarised the findings of 10 earlier trials of which only two have ever been published in the scientific literature. The two trials that were published were funded by Roche, authored by Roche employees and Roche-paid “external” experts. The results of eight key trials of Tamiflu were never fully published, and a brief summary concluded that there was insufficient data to show it reduced complications. This means the data is not reliable enough.
Realising that Keiji Hayashi was quite right, Tom Jefferson contacted Roche and asked for the missing data. This was the beginning of what has so far been a three-year battle and which led to the BMJ’s open data campaign.
In an open letter to Roche about the Tamiflu trial data, BMJ editor, Fiona Godlee wrote “The Cochrane reviewers now know that there are at least 123 trials of oseltamivir [Tamiflu] and that most (60%) of the patient data from Roche’s phase 3 completed treatment trials remain unpublished. We have concerns on a number of fronts: the likely overstating of effectiveness and the apparent under-reporting of potentially serious adverse effects.” (3)
After three frustrating years of trying to get access to the data, Tom Jefferson and his colleagues have given the BMJ their entire email correspondence with Roche, and shared their correspondence with the World Health Organisation (WHO) and the US Centers for Disease Control and Prevention. (1)
WHO’s independence questioned
Questions were raised in 2010 about the role of WHO and the secrecy surrounding the identities of the 16 emergency committee members formed to advise it on the H1N1 pandemic. Articles published in the BMJ in June 2010 raised concerns about whether the pharmaceutical industry had insiders on the WHO emergency committee. (4)
In February 2012 Tom Jefferson emailed WHO, asking WHO scientists how its review process had led to it including Tamiflu in its March 2011 “essential medicines” list. Had it asked the manufacturers of neuraminidase inhibitors such as Tamiflu and Relenza for the unpublished trial data? And what had they made of Cochrane’s conclusion “that there is no evidence that oseltamivir can limit the spread of influenza.”
WHO told Tom Jefferson that it had commissioned several evidence reviews, including one on Tamiflu that would shortly appear in a peer reviewed medical journal. It promised to alert him when the review appeared. (5)
Tom Jefferson was even less impressed with the response he received from the Center for Disease Control. Even the US Food and Drug Administration described Tamiflu’s effects as modest.
“Despite this, WHO and CDC have been extensively promoting the drug. WHO has made Tamiflu one of the essential drugs, so it sits next door to aspirin, penicillin, cortisone,” he said.
Ben Goldacre says in his new book, “Drug companies around the world have produced some of the most amazing innovations of the past fifty years, saving lives on an epic scale. But that does not allow them to hide data, mislead doctors, and harm patients.” (2)
In New Zealand we have Medsafe. But the only information on Tamiflu on Medsafe’s website is produced by Roche which claims that Tamiflu can prevent you from catching the flu. (6) There is actually no evidence that Tamiflu is any better than an aspirin.
2. Ben Goldacre. “Bad Pharma.” Fourth Estate. 2012.
5. David Payne. “Tamiflu: the battle for secret drug data.” British Medical Journal. 2012;345:e7303
THE MYTH OF RESEARCH & DEVELOPMENT COSTS
Numerous books, a growing torrent of papers in medical journals as well as occasional media reports have all attempted to alert governments, health departments and the general public to the growing health crisis caused by the way in which the pharmaceutical industry operates.
In August and September 2012 the British Medical Journal (BMJ) featured two articles that revealed how drug companies put profits before the development of new drugs, choosing instead to tinker with existing drugs and produce minor variations that offer few advantages but result in a steady stream of profits. In the process they have also produced an epidemic of serious adverse reactions that have added to national healthcare costs. (1) (2)
In a paper entitled “Pharmaceutical research and development: what do we get for all that money?” published on 7 August 2012, Professors Donald Light and Joel Lexchin reveal how the drug companies exaggerate research and development costs in order to lobby for more protection from free market competition. An independent analysis found that only 1.3% of revenues are devoted to discovering new molecules compared with an estimated 25% spent on promoting their drugs, giving a ratio of basic research to marketing of 1:19.
While the pharmaceutical industry continues to churn out numerous articles claiming that the costs of research and development are unsustainable for the small number of new drugs that are approved, figures show that the reported costs rose by $34.2 billion between 1995 and 2010, but revenues increased six times faster – by $200.4 billion. The authors of the paper reveal how the hidden business model for pharmaceutical research, sales and profits depends on turning out scores of minor variations on existing drugs, some of which become market blockbusters.
An analysis of Canada’s pharmaceutical expenditure found that 80% of the increase in its drug budget is spent on new, patented medicines that did not offer substantial improvements on less expensive alternatives available before 1990. (3) The major contributors to the increase in costs are the newer hypertension, gastrointestinal, and cholesterol drugs, including atorvastatin, the fifth statin on the Canadian market.
Along with this, independent reviews have concluded that about 85-90% of all new drugs over the past 50 years have provided few benefits and considerable harms. One study found that 29% of the new biological drugs approved by the European Medicines Agency (EMA) received safety warnings within the first 10 years on the market, and therapeutically similar drugs by definition have no advantages to offset their unknown risk of increased harm. (4)
Another paper by Corinna Sorenson and colleagues appeared in the BMJ in September 2012. “Evidence of comparative efficacy should have a formal role in European drug approvals” argued that drug manufacturers should have to show how their new drugs compare to existing medicines before the EMA approves them. (2)
The lack of early comparative efficacy evidence can result in the widespread use of potentially less efficacious and unsafe drugs. An example of this is the diabetes drug rosiglitazone. The relative effectiveness of rosiglitazone as compared to the existing drug treatment for diabetes emerged only after years of widespread use, with rosiglitazone being shown to increase the risk of heart attacks and cardiovascular death. (2)
By requiring the drug companies to prove that their new drug offers a therapeutic advantage over older, less costly medicines before they are approved, the authors claim that clinicians, patients and other healthcare decision-makers will be able to determine whether a new drug is superior, equivalent, or inferior to the existing alternatives.
It will also reduce the toll of morbidity and mortality in patients who currently are being used as guinea pigs in what are in essence unofficial and unacknowledged drug trials.
3. SG Morgan et al. “”Breakthrough” drugs and growth in expenditure on prescription drugs in Canada.” British Medical Journal 2005;331:815-6.
4. TJ Giezen et al. “Safety-related regulatory actions for biologicals approved in the United States and the European Union.” Journal of American Medical Association 2008;300:1887-96.